Clinical trial Recruiting at 2 sites Interventional Ages 21 and up

Messaging about lower-nicotine cigarettes and related policies.

Official title: Communicating About Nicotine and Differential Risks of Tobacco Products in Priority Populations

Run by Georgia State University · NCT06787937 · Data updated 2026-11-12

This study will test whether giving adult smokers very low-nicotine cigarettes together with messages about reduced nicotine and policy changes helps them smoke less than giving the cigarettes without those messages.

Quick facts

Study typeInterventional
Ages21 Years and up
SexAll
Enrollment1230 (estimated)
SponsorGeorgia State University
Academic / other
Locations2 sites (Atlanta, Georgia and 1 other locations)
StatusRecruiting
StartedSeptember 11, 2025
Main results expectedJanuary 31, 2029
Study endsJanuary 31, 2029
Registry record updatedNovember 4, 2026
Trial IDNCT06787937 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 21 or older who are regular smokers (≥100 lifetime cigarettes, smoking on at least 27 of the last 30 days, and CO ≥6 ppm), can read and speak English, are available for the study period, and are willing to try research cigarettes.

Probably not a fit

People who are pregnant or breastfeeding, unwilling to use research cigarettes, not regular smokers, or who cannot attend weekly in-person visits are unlikely to benefit from this specific study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, open-label, two-site study comparing two groups of adult smokers who use very low nicotine cigarettes (VLNCs): one group receives VLNCs plus a campaign of messages about reduced nicotine and policy, and the other receives VLNCs with neutral, non-tobacco messages. Participants include smokers with past-month serious psychological distress (SPD), smokers with low socioeconomic status (SES), and smokers in neither category. Messaging will be delivered via cigarette-pack inserts, print ads, and videos shown at weekly visits, and all participants will attend a 1-week baseline followed by a 4-week intervention period with weekly surveys, breath CO samples, and VLNC supply. Outcomes focus on changes in cigarette use and attitudes toward VLNCs and nicotine policy.

Why it matters

Potential benefit: If successful, combining messages with very low nicotine cigarettes could help smokers reduce the number of cigarettes they smoke and shift attitudes that support nicotine-reduction policies.

How similar studies have gone: Prior clinical work has shown that very low nicotine cigarettes can reduce smoking and dependence, but combining VLNC use with a targeted messaging campaign about nicotine reduction and policy is a relatively new approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 21+ years
* Current smoker (self-report as having smoked 100 cigarettes in their lifetime and currently smoking on 27+ days out of past 30, expired breath carbon monoxide \[CO\] ≥6ppm to assess regular smoking)
* Can speak, read, and write in English
* Available for period of study
* Willing to try novel research cigarettes

Exclusion Criteria:

* Pregnancy or lactation
* Member of the same household as a study subject
* Unwilling to use research cigarettes as part of the trial

Where it's running

  • Georgia State university
    Atlanta, Georgia, United States
    Recruiting
  • Emory University
    Atlanta, Georgia, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.